Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sangamo Therapeutics, Inc. (SGMO : NSDQ)
 
 • Company Description   
Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States.

Number of Employees: 431

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.14 Daily Weekly Monthly
20 Day Moving Average: 1,656,819 shares
Shares Outstanding: 146.69 (millions)
Market Capitalization: $607.28 (millions)
Beta: 1.63
52 Week High: $12.83
52 Week Low: $3.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.02% -2.05%
12 Week -27.50% -20.30%
Year To Date -44.80% -34.83%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7000 MARINA BLVD
-
BRISBANE,CA 94005
USA
ph: 510-970-6000
fax: 510-236-8951
investor@sangamo.com http://www.sangamo.com
 
 • General Corporate Information   
Officers
Alexander D. Macrae - President; Chief Executive Officer
H. Stewart Parker - Director and Chair of the Board
Prathyusha Duraibabu - Senior Vice President and Chief Financial Officer
Robert F Carey - Director
Kenneth J. Hillan - Director

Peer Information
Sangamo Therapeutics, Inc. (CORR.)
Sangamo Therapeutics, Inc. (RSPI)
Sangamo Therapeutics, Inc. (CGXP)
Sangamo Therapeutics, Inc. (BGEN)
Sangamo Therapeutics, Inc. (GTBP)
Sangamo Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 800677106
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 146.69
Most Recent Split Date: 6.00 (1.25:1)
Beta: 1.63
Market Capitalization: $607.28 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.41 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 8.56% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.82
Price/Cash Flow: -
Price / Sales: 5.39
EPS Growth
vs. Year Ago Period: 6.25%
vs. Previous Quarter: -15.38%
Sales Growth
vs. Year Ago Period: 7.42%
vs. Previous Quarter: 0.88%
ROE
03/31/22 - -45.17
12/31/21 - -42.04
09/30/21 - -39.90
ROA
03/31/22 - -23.64
12/31/21 - -22.24
09/30/21 - -21.19
Current Ratio
03/31/22 - 2.87
12/31/21 - 3.12
09/30/21 - 3.39
Quick Ratio
03/31/22 - -
12/31/21 - 3.12
09/30/21 - 3.39
Operating Margin
03/31/22 - -156.53
12/31/21 - -161.05
09/30/21 - -167.16
Net Margin
03/31/22 - -156.53
12/31/21 - -161.05
09/30/21 - -167.16
Pre-Tax Margin
03/31/22 - -156.44
12/31/21 - -160.79
09/30/21 - -166.79
Book Value
03/31/22 - 2.28
12/31/21 - 2.58
09/30/21 - 2.79
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©